• The number of people reporting symptoms of dermatitis will increase from 9.5 to 9.7 million across the countries covered in this report over our ten-year forecast period.
  • People younger than age 20 account for one-third of all dermatitis cases.
  • About one-third of dermatitis cases are associated with atopy.

Table of contents

  • Atopic Dermatitis/Atopic Eczema - Epidemiology - Europe

Author(s): Devashri Mukherjee, MPH; Lade Ayodele

Research enthusiast with a flair for academic writing, member of the DRG family since April 2015 and working from the India office.

Started off career with a bachelor’s in Dental Surgery followed by a master’s in Public health; having primarily worked in the hospital setting as a Research Consultant prior to DRG and with 10 international publications to my credit.

Dr. Ayodele has expertise in forecasting disease populations and is an epidemiology expert in chronic diseases including cancers and cardiovascular diseases, in both the major and emerging pharmaceutical markets.

Prior to joining Decision Resources Group, she researched antiretroviral therapy funding, availability and access at the Clinton Foundation Center for Strategic HIV Operations Research. More recently, she was a Medical Innovation and Leadership fellow at Blue Cross Blue Shield of Massachusetts, where she researched and developed strategic plans on health care utilization and quality improvement. Dr. Ayodele holds a Master in Public Health degree (quantitative methods concentration) from Harvard and a medical degree from the University of Ibadan in Nigeria. She is currently pursuing a Ph.D. in epidemiology at Boston University School of Public Health with a focus in pharmacoepidemiology.


Related Reports

Atopic Dermatitis/Atopic Eczema - Landscape & Forecast - Disease Landscape & Forecast

Atopic dermatitis (AD) is a chronic inflammatory skin disease marked by pruritus and eczema; the main goals of treatment are to protect the skin barrier, redu...

View Details

Atopic Dermatitis/Atopic Eczema - Unmet Need - Detailed, Expanded Analysis - Moderate To Severe (US/EU)

The moderate to severe atopic dermatitis (AD) market is at the beginning of a revolution with the recent approval of Sanofi/Regeneron’s first-in-class b...

View Details